Bioaffinity Technologies files Form S-1, Registration for Securities / Prospectus, with SEC on September20, 2023. The company identifies Cypath Lung (trademarked) technology as using “a synthetic porphyrin called meso-tetra (4-carboxyphenyl) porphyrin (“TCPP”). Porphyrins are biological pigments that, when exposed to ultraviolet light at certain wavelengths, can result in the cell fluorescing a red or purplish…
Bioaffinity Technologies With UV Detectable Lung Cancer Cell Technology Files S-1 With SEC
More from InformationalMore posts in Informational »
- UV Business News – Alliance Group Has Installed World’s Largest Supercritical UV Water Treatment System
- Comprehensive Review of AOP Processes For Minicipal Wastewater Disinfection Including UV Light Production of Ozone
- UV Business News – Arrive AI Inc. Files Form S-1 With SEC
- Review Article Of Managing Ethylene In Produce Ripening Including Use of Oxidative UV
- Surface Emissions Of Volatile Organic Compounds From Surfaces During Use of UVC Irradiation Disinfection